Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials
Open accessThe DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Abstract
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders having a high influence on social interactions. The number of approved treatments and clinical trials for ADHD have increased markedly during the recent decade. This analytical review provides a quantitative overview of the existing pharmacological and non-pharmacological methods of ADHD treatments investigated in clinical trials during 1999–2021. A total of 695 interventional trials were manually assessed from clinicaltrial.gov with the search term « ADHD», and trial data has been used for analysis. A clear majority of the studies investigated non-pharmacological therapies (∼80%), including many behavioral options, such as social skills training, sleep and physical activity interventions, meditation and hypnotherapy. Devices, complementary and other alternative methods of ADHD treatment are also gaining attention. The pharmacological group accounts for ∼20% of all the studies. The most common drug classes include central nervous system stimulants (e.g., methylphenidate hydrochloride, lisdexamfetamine dimesylate, amphetamine sulfate, mixed amphetamine salts, a combination of dexmethylphenidate hydrochloride and serdexmethylphenidate chloride), selective noradrenaline reuptake inhibitors (atomoxetine, viloxazine), and alpha2 adrenergic receptor agonists (guanfacine hydrochloride, clonidine hydrochloride). Several studies investigated antidepressants (e.g., bupropion hydrochloride, vortioxetine), and atypical antipsychotics (e.g., quetiapine, aripiprazole) but these are yet not approved by the FDA for ADHD treatment. We discuss the quantitative trends in clinical trials and provide an overview of the new drug agents and non-pharmacological therapies, drug targets, and novel treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Trends in GPCR drug discovery: new agents, targets and indications
Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B., & Gloriam, D. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.178 · Cited by 2,627 · cited 1×
“Many of these neurotransmitters mediate their effects through G-protein coupled receptors (GPCRs) (Lagerstrom and Schioth, 2008; Hauser et al., 2017) and are transported by corresponding”
BackgroundSelf-citationCortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., Atkinson, L. Z., Tessari, L., Banaschewski, T., Coghill, D., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30269-4 · Cited by 1,716
Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis
Simon, V., Czobor, P., Bálint, S., Mészáros, Á., & Bitter, I. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.048827 · Cited by 1,601
Structural diversity of G protein-coupled receptors and significance for drug discovery
Lagerström, M. C., & Schiöth, H. B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2518 · Cited by 1,492
Self-citationBrunoni, A. R., Nitsche, M. A., Bolognini, N., Bikson, M., Wagner, T., Merabet, L., Edwards, D. J., Valero-Cabre, A., Rotenberg, A., Pascual-Leone, A., et al. (2012) · Brain stimulation · doi:10.1016/j.brs.2011.03.002 · Cited by 1,445 · cited 1×
“It is a non-invasive, painless method of treatment that uses direct electrical currents to stimulate specific parts of the brain (Brunoni et al., 2012).”
MethodSonuga-Barke, E. J. S., Brandeis, D., Cortese, S., Daley, D., Ferrin, M., Holtmann, M., Stevenson, J., Danckaerts, M., van der Oord, S., Döpfner, M., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12070991 · Cited by 1,167 · cited 3×
“For other types of therapies evidence of efficacy from blinded assessments was needed (Sonuga-Barke et al., 2013).”
BackgroundMethodAttention deficit hyperactivity disorder
Thapar, A., & Cooper, M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00238-x · Cited by 1,043
Song, P., Zha, M., Yang, Q., Zhang, Y., Li, X., & Rudan, I. (2021) · Journal of Global Health · doi:10.7189/jogh.11.04009 · Cited by 896 · cited 1×
“The disorder affects around 5% of children and adolescents (Song et al., 2021) and 2.”
BackgroundExercise and Children’s Intelligence, Cognition, and Academic Achievement
Tomporowski, P. D., Davis, C. L., Miller, P. H., & Naglieri, J. A. (2008) · Educational Psychology Review · doi:10.1007/s10648-007-9057-0 · Cited by 874 · cited 1×
“to improvements in executive functions (Tomporowski et al., 2008; Wigal et al., 2013).”
Reenvisioning Clinical Science: Unifying the Discipline to Improve the Public Health
Onken, L. S., Carroll, K. M., Shoham, V., Cuthbert, B. N., & Riddle, M. (2014) · Clinical Psychological Science · doi:10.1177/2167702613497932 · Cited by 872 · cited 1×
“For example, NIH proposes to classify behavioral therapy trials based on the setting of a trial, starting from basic science in the research setting and finishing with trials in community settings (Onken et al., 2014).”
BackgroundTrends in the exploitation of novel drug targets
Rask-Andersen, M., Almén, M. S., & Schiöth, H. B. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3478 · Cited by 853 · cited 1×
“These trends partially correspond to overall trends in drug discovery, where receptors also represent the main drugged class (Rask-Andersen et al., 2011).”
BackgroundSelf-citationTrends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Self-citationTherapeutic application of repetitive transcranial magnetic stimulation: a review
Wassermann, E. M., & Lisanby, S. H. (2001) · Clinical Neurophysiology · doi:10.1016/s1388-2457(01)00585-5 · Cited by 601 · cited 1×
“disorders such as depression, schizophrenia, Tourette’s syndrome, and other (Ziemann et al., 1997; Wassermann and Lisanby, 2001).”
BackgroundSharma, A., & Couture, J. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028013510699 · Cited by 516
Transcranial Direct Current Stimulation (tDCS): A Beginner's Guide for Design and Implementation
Thair, H., Holloway, A. L., Newport, R., & Smith, A. D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00641 · Cited by 513 · cited 1×
“The stimulation arises by providing a constant weak current through two electrodes (anodal and cathodal) placed over the head, which subsequently leads to modulation of neuronal activity (Thair et al., 2017; Chase et al., 2020).”
BackgroundDrug repositioning: a brief overview
Jourdan, J.-P., Bureau, R., Rochais, C., & Dallemagne, P. (2020) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13273 · Cited by 470
Catalá-López, F., Hutton, B., Núñez-Beltrán, A., Page, M. J., Ridao, M., Macías Saint-Gerons, D., Catalá, M. A., Tabarés-Seisdedos, R., & Moher, D. (2017) · PLOS ONE · doi:10.1371/journal.pone.0180355 · Cited by 396 · cited 5×
“Moreover, it was suggested that treatment effects of behavioral therapy were larger when combined with stimulants (Catala-Lopez et al., 2017).”
BackgroundInfluentialArnsten, A. F. T., & Pliszka, S. R. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.01.020 · Cited by 383 · cited 1×
“such as attention, thinking, learning, inhibitory control, impact emotions, behavior, actions, and are associated with many symptoms such as distractibility, forgetfulness, impulsivity, poor planning, and hyperactivity, which are commonly encountered in patients with ADHD (Arnsten, 2006; Arnsten and Pliszka, 2011; Kes…”
BackgroundDecreased motor inhibition in Tourette's disorder: evidence from transcranial magnetic stimulation
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.9.1277 · Cited by 383 · cited 1×
“disorders such as depression, schizophrenia, Tourette’s syndrome, and other (Ziemann et al., 1997; Wassermann and Lisanby, 2001).”
BackgroundFundamentals of Attention-Deficit/Hyperactivity Disorder: Circuits and Pathways
Arnsten, A. F. T. (2006) · The Primary Care Companion to The Journal of Clinical Psychiatry · Cited by 378
Long-Term Outcomes of ADHD: A Systematic Review of Self-Esteem and Social Function
Harpin, V., Mazzone, L., Raynaud, J. P., Kahle, J., & Hodgkins, P. (2016) · Journal of Attention Disorders · doi:10.1177/1087054713486516 · Cited by 370 · cited 1×
“Lastly, it is also important to investigate how available and future treatment options (including non-pharmacological ones) impact the person’s social life and career longitudinally since these longterm outcome measures are effectively one of the main reasons to treat ADHD in the first place (Harpin et al., 2016).”
BackgroundAn analysis of rat prefrontal cortex in mediating executive function
Kesner, R. P., & Churchwell, J. C. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.07.002 · Cited by 366
Understanding Attention-Deficit/Hyperactivity Disorder from Childhood to Adulthood
Wilens, T. E., & Spencer, T. J. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.09.2206 · Cited by 324 · cited 1×
“Attention-deficit/hyperactivity disorder (ADHD) is a neurobehavioral disorder, which can be reliably diagnosed in children, adolescents, and adults (Wilens and Spencer, 2010; Brown et al., 2018).”
BackgroundTreatment strategies for ADHD: an evidence-based guide to select optimal treatment
Caye, A., Swanson, J. M., Coghill, D., & Rohde, L. A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0116-3 · Cited by 303 · cited 2×
“Moreover, they have lower education attainment, are easily distracted, are prone to substance misuse, and more frequently get in serious road traffic accidents (Alternative treatments for attention deficit hyperactivity disorder, 2003; Caye et al., 2019).”
BackgroundChase, H. W., Boudewyn, M. A., Carter, C. S., & Phillips, M. L. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0499-9 · Cited by 286 · cited 1×
“The stimulation arises by providing a constant weak current through two electrodes (anodal and cathodal) placed over the head, which subsequently leads to modulation of neuronal activity (Thair et al., 2017; Chase et al., 2020).”
BackgroundHow much do clinical trials cost?
Martin, L., Hutchens, M., Hawkins, C., & Radnov, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.70 · Cited by 262
Attention Deficit Hyperactivity Disorder:Diagnosis and Management
Boon‐yasidhi, V. (2013) · Journal of the Psychiatric Association of Thailand · Cited by 244
Practitioner Review: Non‐pharmacological treatments for ADHD: A lifespan approach
Young, S., & Myanthi Amarasinghe, J. (2010) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2009.02191.x · Cited by 224
Poelmans, G., Pauls, D. L., Buitelaar, J. K., & Franke, B. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10070948 · Cited by 223
Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways.
Arnsten, A. F. T. (2006) · PubMed · Cited by 208
Lambez, B., Harwood-Gross, A., Golumbic, E. Z., & Rassovsky, Y. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.10.007 · Cited by 207
Catecholamine Dysfunction in Attention-Deficit/Hyperactivity Disorder: An Update
Prince, J. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318174f92a · Cited by 205 · cited 2×
“Patients with ADHD notoriously have depleted levels of these catecholamines (Prince, 2008), so, viloxazine has become the perfect candidate for ADHD treatment and showed significant results in several randomized clinical trials (Findling et al., 2021).”
BackgroundBrioni, J. D., Esbenshade, T. A., Garrison, T. R., Bitner, S. R., & Cowart, M. D. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166876 · Cited by 203 · cited 1×
“2 clinical trials where they did not display significant effectiveness in reducing ADHD symptoms (Brioni et al., 2011; Herring et al., 2012; Weisler et al., 2012).”
BackgroundMolecular targets of atypical antipsychotics: From mechanism of action to clinical differences
Aringhieri, S., Carli, M., Kolachalam, S., Verdesca, V., Cini, E., Rossi, M., McCormick, P. J., Corsini, G. U., Maggio, R., & Scarselli, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.012 · Cited by 199 · cited 1×
“(gene names: DRD2, HTR2A, respectively) are the key targets of antipsychotics (Aringhieri et al., 2018; Kondej et al., 2018).”
BackgroundThe Potential for Misuse and Abuse of Medications in ADHD: A Review
Clemow, D. B., & Walker, D. J. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.09.2801 · Cited by 198 · cited 2×
“dexmethylphenidate hydrochloride and serdexmethylphenidate (represents central nervous system stimulant class) have been approved for ADHD treatment in 2021 (Clemow and Walker, 2014).”
BackgroundHow to avoid common problems when using ClinicalTrials.gov in research: 10 issues to consider
Tse, T., Fain, K. M., & Zarin, D. A. (2018) · BMJ · doi:10.1136/bmj.k1452 · Cited by 188 · cited 1×
“gov–one of the largest web-based resources providing access to summary information on clinical studies on a wide variety of diseases and conditions (Tse et al., 2018).”
BackgroundThe Histamine H3 Receptor: Structure, Pharmacology, and Function
Nieto-Alamilla, G., Márquez-Gómez, R., García-Gálvez, A.-M., Morales-Figueroa, G.-E., & Arias-Montaño, J.-A. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.104752 · Cited by 185
Fredriksson, R., Nordström, K. J. V., Stephansson, O., Hägglund, M. G. A., & Schiöth, H. B. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.10.016 · Cited by 175 · cited 1×
“transporters (Fredriksson et al., 2008; Rask-Andersen et al., 2013); both of which are important classes of drug targets.”
BackgroundSelf-citationHistamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases
Sadek, B. S., Saad, A. K., Sadeq, A. S., Jalal, F. Y., & Stark, H. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.06.051 · Cited by 162 · cited 1×
“To date, it is considered that genetic and pharmacological targeting of histamine receptor H3 alters the level of aggression, circadian rhythms, anxiety, memory, and social behavior and has therapeutic effects on cognitive symptoms in brain disorders (Schneider et al., 2014; Sadek et al., 2016; Reichmann et al., 2020).”
BackgroundHistamine in Neurotransmission and Brain Diseases
Nuutinen, S., & Panula, P. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-8056-4_10 · Cited by 161 · cited 1×
“behavior, memory, sleep-wake cycle (Nuutinen and Panula, 2010; Passani et al., 2014), and be involved in diverse behavior and neuropsychiatric diseases (Nieto-Alamilla et al.”
BackgroundHirota, T., Schwartz, S., & Correll, C. U. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.11.009 · Cited by 161
The roles of histamine and its receptor ligands in central nervous system disorders: An update
Hu, W., & Chen, Z. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.039 · Cited by 138
Transcranial Magnetic Stimulation as Treatment in Multiple Neurologic Conditions
Iglesias, A. H. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-1021-0 · Cited by 132 · cited 2×
“method, where a changing magnetic field is used to cause electric current, which subsequently generates the stimulation of brain neurons (Iglesias, 2020).”
MethodTranscranial direct current brain stimulation decreases impulsivity in ADHD
Allenby, C., Falcone, M., Bernardo, L., Wileyto, E. P., Rostain, A., Ramsay, J. R., Lerman, C., & Loughead, J. (2018) · Brain Stimulation · doi:10.1016/j.brs.2018.04.016 · Cited by 128 · cited 1×
“Also, in patients affected by this disease, tDCS is considered to alleviate symptoms of impulsivity (Allenby et al., 2018).”
BackgroundNon-pharmacological interventions for adult ADHD: a systematic review
Nimmo-Smith, V., Merwood, A., Hank, D., Brandling, J., Greenwood, R., Skinner, L., Law, S., Patel, V., & Rai, D. (2020) · Psychological Medicine · doi:10.1017/s0033291720000069 · Cited by 126 · cited 2×
“There are several reviews about the field of ADHD treatment (Sonuga-Barke et al., 2013; Catala-Lopez et al., 2017; Cortese et al., 2018; Lambez et al., 2020; Nimmo-Smith et al., 2020).”
BackgroundAyano, G., Yohannes, K., & Abraha, M. (2020) · Annals of General Psychiatry · doi:10.1186/s12991-020-00271-w · Cited by 123
Soluble ligands as drug targets
Attwood, M. M., Jonsson, J., Rask‐Andersen, M., & Schiöth, H. B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0078-4 · Cited by 120 · cited 1×
“gov in a similar way as we have done previously (Attwood et al., 2020; Attwood et al., 2021).”
ResultSelf-citationBrown, K. A., Samuel, S., & Patel, D. R. (2018) · Translational Pediatrics · doi:10.21037/tp.2017.08.02 · Cited by 115 · cited 2×
“) (Catala-Lopez et al., 2015; Catala-Lopez et al., 2017; Brown et al., 2018) 2) Non-pharmacological interventions: - psychological: • Behavior management interventions (parent training, classroom interventions, peer-based interventions, classical contingency management, cognitive behavior therapy, organizational skill…”
BackgroundSolute carriers as drug targets: Current use, clinical trials and prospective
Rask‐Andersen, M., Masuram, S., Fredriksson, R., & Schiöth, H. B. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.07.015 · Cited by 110 · cited 1×
“transporters (Fredriksson et al., 2008; Rask-Andersen et al., 2013); both of which are important classes of drug targets.”
BackgroundSelf-citationMulti-Target Approach for Drug Discovery against Schizophrenia
Kondej, M., Stępnicki, P., & Kaczor, A. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103105 · Cited by 110 · cited 1×
“(gene names: DRD2, HTR2A, respectively) are the key targets of antipsychotics (Aringhieri et al., 2018; Kondej et al., 2018).”
BackgroundVeloso, A. S., Vicente, S., & Filipe, M. G. (2020) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.02983 · Cited by 107 · cited 1×
“The effectiveness of cognitive therapies can be related to the ability of such therapies to target the key elements of cognition and intelligence, such as attention, inhibitory control, working memory, planning, and cognitive flexibility that contribute to thinking and learning impaired in patients with ADHD (Veloso e…”
BackgroundProof-of-concept study of an at-home, engaging, digital intervention for pediatric ADHD
Davis, N. O., Bower, J., & Kollins, S. H. (2018) · PLOS ONE · doi:10.1371/journal.pone.0189749 · Cited by 106
Weisler, R. H., Pandina, G., Daly, E., Cooper, K., & Gassmann-Mayer, C. (2012) · CNS Drugs · doi:10.2165/11631990-000000000-00000 · Cited by 103 · cited 1×
“2 clinical trials where they did not display significant effectiveness in reducing ADHD symptoms (Brioni et al., 2011; Herring et al., 2012; Weisler et al., 2012).”
BackgroundSuarez-Manzano, S., Ruiz-Ariza, A., De La Torre-Cruz, M., & Martínez-López, E. J. (2018) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2018.03.015 · Cited by 97 · cited 1×
“Many studies have shown positive effects on academic performance, behavior problems, motor and emotional control, planning and problem-solving (SanchezLopez et al., 2015; Suarez-Manzano et al., 2018).”
BackgroundYu, C., Garcia-Olivares, J., Candler, S., Schwabe, S., & Maletic, V. (2020) · Journal of Experimental Pharmacology · doi:10.2147/jep.s256586 · Cited by 96 · cited 1×
“The main action of viloxazine is to increase the brain norepinephrine concentrations, but it is also considered to facilitate the neurotransmission of serotonin, and, to a lesser extent, dopamine (Yu et al., 2020; Findling et al., 2021).”
BackgroundModulation of behavior by the histaminergic system: Lessons from HDC-, H3R- and H4R-deficient mice
Schneider, E. H., Neumann, D., & Seifert, R. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.07.020 · Cited by 95 · cited 1×
“To date, it is considered that genetic and pharmacological targeting of histamine receptor H3 alters the level of aggression, circadian rhythms, anxiety, memory, and social behavior and has therapeutic effects on cognitive symptoms in brain disorders (Schneider et al., 2014; Sadek et al., 2016; Reichmann et al., 2020).”
BackgroundRapidly rising clinical trial costs worry researchers
Collier, R. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.082041 · Cited by 94 · cited 1×
“Besides, the process of conducting pharmacological clinical trials is extremely costly (ASPE, 2014; Collier, 2009; Martin et al., 2017), which can also contribute to the growth in the quantity of non-pharmacological trials.”
BackgroundExercise: Applications to Childhood ADHD
Wigal, S. B., Emmerson, N., Gehricke, J.-G., & Galassetti, P. (2013) · Journal of Attention Disorders · doi:10.1177/1087054712454192 · Cited by 93 · cited 1×
“to improvements in executive functions (Tomporowski et al., 2008; Wigal et al., 2013).”
Behavior Management for School-Aged Children with ADHD
Pfiffner, L. J., & Haack, L. M. (2014) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2014.05.014 · Cited by 89 · cited 1×
“Behavioral therapies happened to be rather effective in eliminating the symptoms of ADHD (Pfiffner and Haack, 2014; Catala-Lopez et al., 2017).”
BackgroundZang, Y. (2019) · Medicine · doi:10.1097/md.0000000000017980 · Cited by 89 · cited 2×
“In some trials, a substantial improvement in anxiety and depression symptoms, aggressive behaviors, and social problems were observed (Zang, 2019).”
BackgroundMethodGenetics of attention-deficit/hyperactivity disorder: an update
Akutagava-Martins, G. C., Rohde, L. A., & Hutz, M. H. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1130626 · Cited by 83
Shrestha, M., Lautenschleger, J., & Soares, N. (2020) · Translational Pediatrics · doi:10.21037/tp.2019.10.01 · Cited by 71 · cited 4×
“) • Psychoeducation (Catala-Lopez et al., 2015; CatalaLopez et al., 2017; Shrestha et al., 2020) - complementary and alternative methods: • Supplementary interventions and dietary interventions (polyunsaturated fatty acids, vitamins, minerals, amino acids, herbal treatment, homeopathic treatment, etc.”
BackgroundInfluentialCook (2014) · doi:10.1016/j.nec.2013.10.002 · Cited by 69 · cited 1×
“cingulate, inferior frontal gyrus, medial and middle frontal gyri known to be important in regulating executive functions that are impaired in patients with ADHD (Cook et al., 2014; Loo et al., 2021).”
BackgroundHaig, G. M., Bain, E., Robieson, W., Othman, A. A., Baker, J. P., & Lenz, R. A. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt240 · Cited by 68 · cited 2×
“The main reason for drug discontinuation was lack of efficacy or safety (e.g., bradanicline, vortioxetine, bavisant, PF-03654746, NS-2359, AZD1446) (Learned et al., 2012; Haig et al., 2014; Pozzi et al., 2020).”
Adler, L. A., Adams, J., Madera‐McDonough, J., Kohegyi, E., Hobart, M., Chang, D., Angelicola, M., McQuade, R. D., & Liebowitz, M. R. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001575 · Cited by 63 · cited 1×
“Phase 3 randomized controlled trails demonstrated centanafadine to be safe, well-tolerated and effective in addressing the core symptoms of ADHD in adults (Adler et al., 2022) Currently, centanafadine is under investigation in several clinical trials assessing its efficacy and safety in children and adolescents with A…”
BackgroundLoo, S. K., Salgari, G. C., Ellis, A. J., Cowen, J., Dillon, A., & McGough, J. J. (2020) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2020.09.021 · Cited by 60 · cited 1×
“cingulate, inferior frontal gyrus, medial and middle frontal gyri known to be important in regulating executive functions that are impaired in patients with ADHD (Cook et al., 2014; Loo et al., 2021).”
BackgroundHeal, D. J., Buckley, N., Gosden, J., Slater, N., France, C. P., & Hackett, D. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.021 · Cited by 55 · cited 1×
“In addition, modafinil–stimulant, initially approved by the FDA as a wakefulness-promoting agent failed to become a treatment option for ADHD patients due to safety concerns (Heal et al., 2013).”
BackgroundEmerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)
Pozzi, M., Bertella, S., Gatti, E., Peeters, G. G. A. M., Carnovale, C., Zambrano, S., & Nobile, M. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1820481 · Cited by 55 · cited 4×
“The main reason for drug discontinuation was lack of efficacy or safety (e.g., bradanicline, vortioxetine, bavisant, PF-03654746, NS-2359, AZD1446) (Learned et al., 2012; Haig et al., 2014; Pozzi et al., 2020).”
BackgroundInfluentialViloxazine in the Management of CNS Disorders: A Historical Overview and Current Status
Findling, R. L., Candler, S. A., Nasser, A. F., Schwabe, S., Yu, C., Garcia-Olivares, J., O’Neal, W., & Newcorn, J. H. (2021) · CNS Drugs · doi:10.1007/s40263-021-00825-w · Cited by 55
Alpha-2 Adrenergic Receptors and Attention-Deficit/Hyperactivity Disorder
Cinnamon Bidwell, L., Dew, R. E., & Kollins, S. H. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0136-4 · Cited by 53
Catalá-López, F., Hutton, B., Núñez-Beltrán, A., Mayhew, A. D., Page, M. J., Ridao, M., Tobías, A., Catalá, M. A., Tabarés-Seisdedos, R., & Moher, D. (2015) · Systematic Reviews · doi:10.1186/s13643-015-0005-7 · Cited by 51 · cited 5×
“) (Catala-Lopez et al., 2015; Catala-Lopez et al., 2017; Brown et al., 2018) 2) Non-pharmacological interventions: - psychological: • Behavior management interventions (parent training, classroom interventions, peer-based interventions, classical contingency management, cognitive behavior therapy, organizational skill…”
BackgroundInfluentialPérez‐Gómez, J., Amigo‐Gamero, H., Collado‐Mateo, D., Barrios-Fernández, S., Bermejo, L. M., García-Gordillo, M. Á., Carlos‐Vivas, J., & Adsuar, J. C. (2021) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.12710 · Cited by 43
Herring, W. J., Wilens, T. E., Adler, L. A., Baranak, C. C., Liu, K., Snavely, D. B., Lines, C. R., & Michelson, D. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07178 · Cited by 41
Wigal, S. B., Wigal, T., Hobart, M., Madera, J. J., Baker, R. A., Kohegyi, E., McKinney, A., & Wilens, T. E. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s242084 · Cited by 41
Cosmo, C. S. A., DiBiasi, M., Lima, V. L. C. C., Grecco, L. A. C., Muszkat, M., Philip, N. S., & de Sena, E. P. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.06.054 · Cited by 40
Hegvik, T.-A., Waløen, K., Pandey, S. K., Faraone, S. V., Haavik, J., & Zayats, T. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0540-z · Cited by 39
Reichmann, F., Rimmer, N., Tilley, C. A., Vecchia, E. D., Pinion, J., Oustah, A. A., Gutiérrez, H. C., Young, A. M. J., McDearmid, J. R., Winter, M. J., et al. (2020) · Acta Physiologica · doi:10.1111/apha.13543 · Cited by 38 · cited 1×
“To date, it is considered that genetic and pharmacological targeting of histamine receptor H3 alters the level of aggression, circadian rhythms, anxiety, memory, and social behavior and has therapeutic effects on cognitive symptoms in brain disorders (Schneider et al., 2014; Sadek et al., 2016; Reichmann et al., 2020).”
BackgroundPassani, M. B., Panula, P., & Lin, J. (2014) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2014.00064 · Cited by 37 · cited 1×
“behavior, memory, sleep-wake cycle (Nuutinen and Panula, 2010; Passani et al., 2014), and be involved in diverse behavior and neuropsychiatric diseases (Nieto-Alamilla et al.”
BackgroundEpstein, J. N., Langberg, J. M., Lichtenstein, P. K., Kolb, R. C., & Simon, J. O. (2013) · Clinical Practice in Pediatric Psychology · doi:10.1037/cpp0000004 · Cited by 37 · cited 1×
“Mehealth for ADHD is an evidencebased, secure online technology portal that helps pediatricians to provide better ADHD care and increases rates of behavioral treatment (Epstein et al., 2013).”
BackgroundComplementary and alternative therapies for children and adolescents with ADHD
Bader, A. L., & ADESMAN, A. R. (2012) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32835a1a5f · Cited by 35 · cited 1×
“) (Bader and Adesman, 2012; Esparham et al., 2014; Catala-Lopez et al., 2015; Sharma et al., 2015; Catala-Lopez et al., 2017; Shrestha et al., 2020) - devices • Transcranial direct current stimulation (tDCS)”
BackgroundOn behalf of the Movi-Kids group, Sánchez-López, M., Pardo-Guijarro, M. J., del Campo, D. G.-D., Silva, P., Martínez-Andrés, M., Gulías-González, R., Díez-Fernández, A., Franquelo-Morales, P., & Martínez-Vizcaíno, V. (2015) · Trials · doi:10.1186/s13063-015-0992-7 · Cited by 34
Pharmacology, Systematic Review and Recent Clinical Trials of Metadoxine
Miceli, M. D., & Gronier, B. (2018) · Reviews on Recent Clinical Trials · doi:10.2174/1574887113666180227100217 · Cited by 34
Learned, S. M., Graff, O. X., Roychowdhury, S. M., Moate, R., Krishnan, K., Archer, G. E., Modell, J. G., Alexander, R., Zamuner, S., Lavergne, A., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111424931 · Cited by 33 · cited 2×
“The main reason for drug discontinuation was lack of efficacy or safety (e.g., bradanicline, vortioxetine, bavisant, PF-03654746, NS-2359, AZD1446) (Learned et al., 2012; Haig et al., 2014; Pozzi et al., 2020).”
Neurostimulation in Treating ADHD.
Wong, H. C., & Zaman, R. (2019) · PubMed · Cited by 31
Faison, S. L., Fry, N., Adewole, T., Odebo, O., Wang, Z., Maletic, V., & Nasser, A. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001361 · Cited by 28 · cited 1×
“Initially, Viloxazine or SPN-812 had been developed and approved in the UK for the treatment of depression, but later it was withdrawn from the market because of business reasons unrelated to the therapeutic effectiveness of the drug or its safety (Faison et al., 2021).”
BackgroundToren, P., Rehavi, M., Luski, A., Roz, N., Laor, N., Lask, M., & Weizman, A. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.07.002 · Cited by 22
The evidence-based pharmacological treatment of paediatric ADHD
Vaughan, B. S., March, J. S., & Kratochvil, C. J. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000095 · Cited by 22 · cited 1×
“Despite the fact, that the number of unique pharmacological interventions is not high (Supplementary Figure S1), drugs remain the first-line treatment of ADHD (Vaughan et al., 2012).”
BackgroundPediatric Integrative Medicine Approaches to Attention Deficit Hyperactivity Disorder (ADHD)
Esparham, A. E., Evans, R., Wagner, L., & Drisko, J. (2014) · Children · doi:10.3390/children1020186 · Cited by 18 · cited 1×
“) (Bader and Adesman, 2012; Esparham et al., 2014; Catala-Lopez et al., 2015; Sharma et al., 2015; Catala-Lopez et al., 2017; Shrestha et al., 2020) - devices • Transcranial direct current stimulation (tDCS)”
BackgroundMoorthy, G., Sallee, F. R., Gabbita, S. P., Zemlan, F. P., Sallans, L., & Desai, P. B. (2015) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1955 · Cited by 18 · cited 1×
“safe, well-tolerated, and showed no serious adverse events in the phase 1 clinical trial (Moorthy et al., 2015).”
BackgroundNon-Pharmacological Treatments for ADHD in Youth
Sharma, A. K., Gerbarg, P. L., & Brown, R. (2015) · Adolescent Psychiatry · doi:10.2174/221067660502150430154937 · Cited by 18
Russell, A. E., Moore, D. A., Sanders, A., Dunn, B. D., Hayes, R. A., Kidger, J., Sonuga-Barke, E. J. S., Pfiffner, L. J., & Ford, T. J. (2022) · Systematic Reviews · doi:10.1186/s13643-022-01902-x · Cited by 11
Old drug tipepidine as new hope for children with ADHD
Hashimoto, K., & Sasaki, T. G. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414553952 · Cited by 7 · cited 1×
“It is assumed that the pharmacological effect of tipepidine on ADHD symptoms is due to the inhibition of G protein-coupled inwardly rectifying potassium (GIRK)-channel currents with the subsequent regulation and balancing of monoamines level in the brain (Hashimoto and Sasaki, 2015) Tipepidine showed some promising re…”
ResultFDA permits marketing of first medical device for treatment of ADHD
(2019) · Case Medical Research · doi:10.31525/fda2-ucm636379.htm · Cited by 5 · cited 2×
“Monarch eTNS System is the first device-basedADHD treatment, that received clearance from the FDA (FDA, 2019).”
BackgroundDasotraline in ADHD: novel or me too drug?
Vandana, P., & Arnold, L. E. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1593826 · Cited by 4
Alternative treatments for attention deficit hyperactivity disorder
(2003) · Paediatrics & Child Health · doi:10.1093/pch/8.4.243 · Cited by 3
Research works printed but not linked: 5
- 2013, Diagnostic and Statistical Manual of Mental Disorders
- Multi-discipline review for AZSTARYS
- Press release Announcement2020
- Press release Announcement2021
- Press release Announcement2022
Cited by
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78
Clark, A., Tate, B., Urban, B., Schroeder, R., Gennuso, S. A., Ahmadzadeh, S., McGregor, D., Girma, B., Shekoohi, S., & Kaye, A. D. (2023) · Health Psychology Research · doi:10.52965/001c.81043 · Cited by 52
Aldakhil, A. F. (2024) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2024.104858 · Cited by 36
Nose to Brain Delivery of Transferrin conjugated PLGA nanoparticles for clonidine
Sharma, S., Tyagi, A. K., & Dang, S. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126471 · Cited by 36
Namiot, E. D., Smirnovová, D., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1228148 · Cited by 32
Self-citation
Metadata
- Authors
- Nazarova, V. A., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B.
- Affiliations
- Uppsala University (SE)
- Corresponding author
- Schiöth, Helgi B.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2022-11-17
- Volume
- 13
- Pages
- 1066988-1066988
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC9713849
- OpenAlex
- W4309604196
- Cited by
- 111
- References
- 96
- Citations by year
- 2026: 24 · 2025: 51 · 2024: 24 · 2023: 12
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Brain Research Foundation
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Keywords
- attention deficit hyperactivity disorder, ADHD treatment, pharmacotherapy, non-pharmacological treatment, psychostimulants, methylphenidate, atomoxetine, guanfacine, clonidine, noradrenergic reuptake inhibitors, antidepressants, atypical antipsychotics, behavioral interventions, social skills training, meditation, hypnotherapy, sleep interventions, physical activity interventions, clinical trial trends, therapeutic target, complementary and alternative medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.